Starting 2026 with a retrospective look at FDA approvals shows orphan drugs holding their ground as the backbone of biopharma innovation — accounting for roughly half of all new approvals over the past three years (28 of 55 in 2023, 26 of 50 in 2024, and 23 of 46 in 2025). 60% of 2025’s orphan approvals targeted non-oncology rare diseases, highlighting unmet medical need and the commercial pull driving developers to invest in rare conditions.
Now, Congress is throwing more fuel on the fire. Lawmakers have reauthorized the Rare Pediatric Disease Priority Review Voucher (PRV) program for another five years, reviving one of the FDA’s most lucrative incentives for rare-disease innovation. The program hands out transferable vouchers — worth hundreds of millions on the secondary market — to companies that bring new pediatric rare disease therapies to market.
The reauthorization comes alongside broader healthcare measures—telehealth extensions, newborn screening upgrades, and Medicaid access reforms—that together reinforce Washington’s renewed focus on patients with the rarest conditions.
1. Clinical news & patient access
January put rare kidney diseases front and center. Advicenne advanced toward a potential first U.S. approval in distal renal tubular acidosis, with the FDA accepting the NDA for Sibnayal® and setting a September PDUFA date. At the same time, Boehringer Ingelheim launched a pivotal Phase 3 trial of its TRPC6 inhibitor apecotrep in focal segmental glomerulosclerosis (FSGS), aiming to deliver the first disease-modifying therapy for a condition long without approved options.
Jan. 19, 2026 – Advicenne – FDA accepts Sibnayal® NDA for distal renal tubular acidosis
Advicenne announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Sibnayal® (ADV7103), a fixed‑dose combination of potassium citrate and potassium hydrogen carbonate that works as an alkalising agent, neutralising excess acid and restoring potassium balance for the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder. The combination in prolonged-release granules allows for steady alkali release over time in an efficient, tolerable and convenient manner. The FDA has set a target PDUFA action date of September 3, 2026, marking a key regulatory milestone toward potential U.S. approval.
Jan. 27, 2026 – Intellia Therapeutics – FDA Lifts Clinical Hold on Nexiguran Ziclumeran for ATTRv‑PN
Intellia Therapeutics announced that the FDA lifted the clinical hold on its Phase 3 MAGNITUDE‑2 trial of nexiguran ziclumeran (NTLA‑2001), an investigational CRISPR‑based gene‑editing therapy for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‑PN), a progressive, nerve‑damaging genetic disorder with limited treatment options. The therapy is delivered as a one-time intravenous infusion. The hold was lifted following additional safety monitoring measures after a liver-related adverse event in a related trial. The MAGNITUDE‑2 trial will resume patient enrollment and dosing, with enhanced liver safety monitoring, while a related trial for the cardiac form of ATTR remains on hold.
Jan. 28, 2026 – Biogen – Breakthrough Therapy for litifilimab in cutaneous lupus erythematosus
Biogen announced that the FDA granted Breakthrough Therapy designation to litifilimab (BIIB059), an investigational monoclonal antibody targeting BDCA2 for cutaneous lupus erythematosus (CLE) — a chronic autoimmune skin disease with no currently approved targeted therapies. The product is administered subcutaneously. This designation is based on Phase 2 data demonstrating improvements in CLE skin disease activity and aims to expedite development and regulatory review as the ongoing Phase 3 AMETHYST study continues. Another study is currently ongoing in systemic lupus erythematosus.
Jan. 28, 2026 – REGENXBIO – FDA places clinical hold on gene therapy programs for Hurler & Hunter syndromes
The FDA placed a clinical hold on two of REGENXBIO’s experimental AAV9 based gene therapy programs administered directly into the cerebrospinal fluid (CSF) via intracisternal injection. A brain tumor was discovered in an asymptomatic trial participant who had received RGX‑111 for Mucopolysaccharidosis type I (Hurler syndrome) about four years earlier. Preliminary genetic analysis of the tumor found evidence that the AAV vector genome integrated near a proto‑oncogene (PLAG1), which is a gene that, when overexpressed, can promote cell growth and potentially contribute to cancer. It is not yet known whether the therapy caused the tumor. Due to shared safety concerns, the hold also applies to RGX‑121, developed for MPS II (Hunter syndrome), affecting ongoing clinical development toward potential approvals.
Jan. 28, 2026 – Boehringer Ingelheim – Phase III pivotal trial launched for FSGS
Boehringer Ingelheim announced the initiation of its pivotal Phase III trial of apecotrep (BI 764198), a TRPC6 inhibitor, in patients with focal segmental glomerulosclerosis (FSGS), a rare kidney disorder characterized by proteinuria and progressive loss of kidney function. This follows positive Phase II data showing a 35% proteinuria response versus 7% for placebo, indicating meaningful biological activity. The Phase III study will randomize 286 patients and assess changes in urine protein-creatinine ratio over 104 weeks, aiming to confirm efficacy and safety. The trial represents a major step toward providing the first FDA-approved therapy for FSGS, an area of high unmet need with no currently approved treatments.
Patient access news
Europe
France’s national medicines agency, ANSM, has introduced a fast-track authorization pathway for certain clinical trials, launching in the first quarter of 2026 as part of the France 2030 health innovation strategy. This accelerated process applies to early-phase (Phase I/I-II) trials, particularly for serious or rare diseases with no approved treatment, first-in-class therapies, or trials including adolescents alongside adults. Under the fast-track system, ANSM aims to grant trial authorization in as few as 14 days if no questions arise, or within 49 days if questions are raised, significantly shortening the traditional review timeline.
For rare disease patients, this initiative offers several key benefits: faster access to potentially life-saving experimental treatments, increased availability of trials in France, inclusion of underserved populations, and accelerated generation of clinical evidence. Sponsors must first obtain pre-eligibility confirmation from ANSM before submitting the trial via the EU’s CTIS portal, ensuring efficiency without compromising safety.
Unites States
Congress Passes Five-Year Reauthorization of Rare Pediatric Disease PRV Program
Congress has given the Rare Pediatric Disease Priority Review Voucher (PRV) program a new lease on life, greenlighting a five-year reauthorization that keeps one of the FDA’s most powerful rare-disease incentives alive. The program, which had expired at the end of 2024, lets drugmakers snag or sell a golden ticket—a priority review voucher—for winning approval of a therapy targeting a rare pediatric condition.
The move is a major win for biotechs in the rare-disease space, where investment can be thin and timelines long. Beyond the PRV revival, the legislation also folds in telehealth extensions, newborn screening boosts, and Medicaid access upgrades. Advocacy from groups like the EveryLife Foundation for Rare Diseases proved pivotal, ensuring Washington kept its foot on the gas for innovation in conditions that desperately need attention.
2. Financings & Partnerships
Raising $82 M in Series A, Mendra aiming at modernizing the development and commercialization of rare disease therapies plans to employ AI to accelerate patient identification, clinical trial enrollment, and access to global markets. The impact of AI extends beyond product commercialization; it plays a transformative role throughout the entire value chain, optimizing processes, improving decision-making, and enabling new forms of value creation.
Jan. 21, 2026 — Mendra raises $82 M in Series A
Deal: San Francisco–based biotech Mendra closed an $82 million Series A financing to acquire, develop, and commercialize therapies for rare diseases. The round was co‑led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. Funds will support building a portfolio of rare disease assets and advancing lead programs toward clinical development.
Type: Series A financing (rare disease biotech)
Jan. 29, 2026 — BioIndustry Association partners with Muscular Dystrophy UK
Deal: The BioIndustry Association (BIA) named Muscular Dystrophy UK as its charity partner for 2026. The partnership aims to raise awareness, support fundraising, and foster collaboration between UK life sciences companies and patient organizations to accelerate research, clinical trial participation, and access to treatments for muscle-wasting rare diseases.
Type: Strategic industry–charity partnership
Jan. 15–26, 2026 — Think Bioscience secures $55 M to advance Noonan syndrome program
Deal: Think Bioscience, a Colorado-based biotech, raised $55 million from investors including Regeneron Ventures and Janus Henderson Investors to advance its lead small molecule program for Noonan syndrome, a rare genetic developmental disorder with limited treatment options.
Type: Series A financing (rare genetic disease)
3. Research breakthroughs
The World Economic Forum highlights a powerful truth: rare disease research is a catalyst for wider medical innovation. From genomics and gene therapy to AI-assisted diagnostics and precision medicine, insights gained from studying rare conditions are transforming how we understand, treat, and prevent disease.
UCL scientists grow mini-stomach organoids to study rare gastric diseases
Researchers at University College London (UCL) and Great Ormond Street Hospital developed the first multi-regional “mini-stomach” organoids, lab-grown models that mimic key anatomical regions of the human stomach. These organoids provide a powerful new tool to explore disease mechanisms and test treatments for rare gastric disorders, improving the ability to model and understand conditions that were previously difficult to study in vitro.
Scientists uncover a previously unknown rare form of neonatal diabetes
An international team led by University of Exeter Medical School and Université Libre de Bruxelles identified a new genetic form of diabetes in newborns, caused by mutations in the TMEM167A gene. The condition is linked not only to insulin production failure but also to neurological issues such as epilepsy and microcephaly. This discovery clarifies a long-standing mystery about early-onset diabetes and opens new avenues for studying both rare and common metabolic disorders.
Rare diseases drive medical innovation, says WEF analysis
A World Economic Forum analysis highlighted how rare disease research accelerates broader medical innovation, including genomics, gene therapy, AI-assisted diagnostics, and precision medicine platforms. Insights from rare disease studies continue to push the frontiers of personalized and data-driven healthcare, catalyzing cross-sector collaboration and improving data infrastructures that benefit both rare and common diseases.
AI model “RareAlert” shows promise for early rare disease detection
Researchers introduced RareAlert, a machine learning framework that integrates reasoning from large language models to predict rare disease risk using routine clinical data. RareAlert achieved high diagnostic screening accuracy (AUC ≈ 0.917) in testing, demonstrating potential for scalable, privacy-preserving early detection of rare conditions in primary care, which could accelerate referral and treatment pathways.
Upcoming events
📅 February 13, 2026 — Rare Disease Symposium 2026 — UCSF (San Francisco, CA, USA)
Hosted by UCSF’s Institute for Human Genetics, this symposium explores diagnostics, therapeutics, and translational advances in rare diseases.
📅 February 23, 2026 — 5th Crick Rare Diseases Conference 2026 — London, UK
Marks Rare Disease Day with cutting-edge basic and translational research updates on rare diseases, featuring talks from scientists, clinicians, and industry partners.
📅 February 23, 2026 — FDA Rare Disease Day Public Meeting 2026 — Virtual (U.S.)
Annual public meeting for patients, advocates, researchers, and industry to discuss regulatory science, patient engagement, and development of medical products for rare diseases.
📅 March 5–6, 2026 — Advancement of Treatments for Rare Diseases 2026 — Nicosia, Cyprus
European meeting focused on regulatory collaboration, research innovation, access, and therapeutic development for rare diseases.
📅 March 10–14, 2026 — Annual Clinical Genetics Meeting (ACMG 2026) — Baltimore, MD, USA
The premier clinical genetics meeting featuring substantial content on rare disease diagnostics, genomics, precision medicine, and gene therapy advances.
📅 May 18–19, 2026 — 15th World Rare Diseases Congress 2026 — Prague, Czech Republic
Global forum covering research, policy, and clinical care for rare and orphan diseases, bringing together scientists, clinicians, advocates, industry, and regulators.
📅 June 3–4, 2026 — European Conference on Rare Diseases & Orphan Products (ECRD 2026) — Prague, CZ & Online
The flagship European policy and advocacy event for rare diseases, led by EURORDIS, addressing healthcare access, research, holistic care, and patient engagement.
📅 June 9–11, 2026 — World Orphan Drug Congress USA 2026 — Boston, MA, USA
One of the largest global gatherings dedicated to rare and orphan drug development, bringing together industry leaders, regulators, investors, and patient advocates.
📅 June 17–18, 2026 — 7th International Conference on Rare Diseases (RARE2026) — Kraków, Poland
Scientific conference covering gene therapy, omics, newborn screening, and translational research with global participation and expert speakers in the rare disease field.